Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Rivaroxaban Plus Aspirin in CLTI Patients with Diabetes, Hypertension, and Hypercholesterolemia
NCT07832578Phase 1Recruiting
- Sponsor
- King Edward Medical University
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised trial of rivaroxaban in chronic limb-threatening ischemia (CLTI) (2 arms), sponsored by King Edward Medical University. Primary endpoints: Major Adverse Limb Events at 6 months and Major Adverse Cardiovascular Events at 6 months. Started Jun 2026; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on NCT07832578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832578.